A Phase II Study of Pelareorep (REOLYSIN(®)) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with 1 and 5-year survival rates of ~18% and 7% respectively. FOLFIRINOX or gemcitabine in combination with nab-paclitaxel are standard treatment options for metastatic disease. However, both regimens are more toxic than gemcitabine alone...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancers (Basel)
Auteurs principaux: Mahalingam, Devalingam, Goel, Sanjay, Aparo, Santiago, Patel Arora, Sukeshi, Noronha, Nicole, Tran, Hue, Chakrabarty, Romit, Selvaggi, Giovanni, Gutierrez, Andres, Coffey, Matthew, Nawrocki, Steffan T., Nuovo, Gerard, Mita, Monica M.
Format: Artigo
Langue:Inglês
Publié: MDPI 2018
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6025223/
https://ncbi.nlm.nih.gov/pubmed/29799479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers10060160
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires